Glyscend Therapeutics is pioneering a novel class of gut-targeted polymer therapies aimed at treating Type 2 Diabetes (T2D) and obesity. Their lead product candidate, GLY-200, represents a first-in-class oral polymeric drug designed to mimic the physiological effects of metabolic surgery, specifically gastric bypass, without the associated risks and invasiveness. This innovative approach involves the formation of a reversible coating in the gastrointestinal (GI) tract, which modulates the mucosal barrier to prevent food interaction with the duodenal mucosal surface. By leveraging their proprietary polymer therapeutic platform, Glyscend aims to provide a safe and effective alternative to traditional metabolic surgery, making treatment more accessible to patients who may not qualify for surgical options.

The company’s extensive background in gastroenterology, metabolism, and polymer chemistry underpins the development of GLY-200, which has shown promising results in preclinical studies. Glyscend's approach not only seeks to address the immediate metabolic challenges posed by T2D and obesity but also aims to deliver therapeutic benefits earlier in the treatment continuum. With a completed Phase 1 study and an ongoing Phase 2 trial, Glyscend is positioned to advance its mission of transforming the management of metabolic diseases through non-invasive, patient-friendly therapies.

United States

Developer of oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety-advantages avoiding invasive complications of surgeries and procedures.

Glyscend Therapeutics

Company Details